Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population

Journal of Parkinson's Disease

Volumn 1, Issue 1, 2011, Pages 35-47

  Chillag Talmor, Orly ^a   Giladi, Nir ^b,c   Linn, Shai ^a,d   Gurevich, Tanya ^b,c   El Ad, Baruch ^b,e   Silverman, Barbara ^e   Friedman, Nurit ^e   Peretz, Chava ^c  

^a UNIVERSITY OF HAIFA   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

drug tracer; incidence; Parkinson's disease; Parkinson's disease drug therapy; prevalence

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ACCURACY; ADULT; AGE; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISRAEL; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATIENT ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PURCHASING; SENSITIVITY ANALYSIS; SEX DIFFERENCE; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIPARKINSON AGENTS; FEMALE; HUMANS; INCIDENCE; ISRAEL; MALE; MIDDLE AGED; PARKINSON DISEASE; POPULATION GROUPS; PREVALENCE; YOUNG ADULT;

EID: 79958232053     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11024     Document Type: Article

References (32)

1. Nebraska Department of Health & Human Services (2007) Nebraska Parkinson's Disease Registry, 2007 http://www.hhs. state.ne.us/ced/parkinsons/, Accessed on March 23, 2008.
2. The Parkinson's Institute (2006) California PD Registry - Legislative History, 2006. http://www.thepi.org/site/ parkinson/section.php?id=92, Accessed on March 23, 2008.
3. Sautter J,Wick R, Adlkofer F, & Baker MG (2003) Research in the European Union. Lancet Neurol, 2, 702-706. (Pubitemid 37311324)
4. Zhang ZX & Roman GC (1993) Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology, 12, 195-208. (Pubitemid 23353338)
5. Checkoway H & Nelson LM (1999) Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology, 10, 327-336. (Pubitemid 29187771)
6. Twelves D, Perkins KS, & Counsell C (2003) Systematic review of incidence studies of Parkinson's disease. Mov Disord, 18, 19-31. (Pubitemid 36150204)
7. de Lau LM & Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol, 5, 525-535. (Pubitemid 44262284)
8. De Pedro Cuesta J & Rosenqvist U(1984) Tracers for paralysis agitans in epidemiological research. Neuroepidemiology, 3, 82-96.
9. Menniti-Ippolito F, Spila-Alegiani S, Vanacore N, Bonifati V, Diana G, Meco G, & Raschetti R (1995) Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Acta Neurol Scand, 92, 49-54.
10. Lai BC, Schulzer M, Marion S, Teschke K, & Tsui JK (2003) The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat Disord, 9, 233-238. (Pubitemid 36292134)
11. Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, & Kessing LV (2006) Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord, 21, 1221-1225. (Pubitemid 44336613)
12. World Health Organization Collaborating Centre for Drug Statistics Methodology (2008) Anatomical Therapeutic Chemical Classification System with Defined Daily Dose (ATC/DDD) Index 2008. http://www.whocc.no/atcddd/, Accessed on January 30, 2008.
13. Aquilonius SM & Hartvig P (1986) A Swedish county with unexpectedly high utilization of anti-parkinsonian drugs. Acta Neurol Scand, 74, 379-382. (Pubitemid 17215195)
14. Martinez-Suarez MM & Blazquez-Menes B (2000) [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs]. Rev Neurol, 31, 1001-1006. (Pubitemid 32148029)
15. National Institute for Health, Clinical Excellence (2006) Parkinson's disease: Diagnosis and management in primary and secondary care. NICE clinical guideline 35, 2006. http://www.nice.org.uk/CG035, Accessed on October 10, 2010.
16. Kuopio AM, Marttila RJ, Helenius H, & Rinne UK (1999) Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology, 52, 302-308. (Pubitemid 29059056)
17. Gibb WR & Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 51, 745-752.
18. Gelb DJ, Oliver E, & Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol, 56, 33-39. (Pubitemid 29046907)
19. Hughes AJ, Daniel SE, Ben-Shlomo Y, & Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 125, 861-870. (Pubitemid 34279780)
20. Israel Central Bureau of Statistics (2006) Statistical abstract of Israel, 2006: Table 2.18 - Population, by population group, religion, sex and age. http://www.cbs.gov.il/reader/shnaton/ templ shnaton.html?num tab=st02 18&CYear=2006, Accessed on October 29, 2009.
21. Lix LM, Hobson DE, Azimaee M, Leslie WD, Burchill C, & Hobson S (2010) Socioeconomic variations in the prevalence and incidence of Parkinson's disease: a population-based analysis. J Epidemiol Community Health, 64, 335-340.
22. Israel Central Bureau of Statistics (2010) Statistical abstract of Israel, 2010: Table 3.24 - Life expectancy, by sex, religion and population group. http://www.cbs.gov.il/ shnaton61/download/st03 24.xls, Accessed on May 8, 2011.
23. von Campenhausen S, Bornschein B,Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, & Dodel R (2005) Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol, 15, 473-490. (Pubitemid 40949553)
24. Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, & Grandjean P (2008) Prevalence and incidence of Parkinson's disease in The Faroe Islands. Acta Neurol Scand, 118, 126-131.
25. Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, & Giladi N (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology, 69, 1595-1602. (Pubitemid 350287143)
26. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa E.R, Bar-Shira A, BergD, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni- Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang A.E, Lee-Chen GJ, Lesage S, Marder K, Mata I.F, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M,Tan EK,Tayebi N, Toda T, Troiano AR, Tsuji S,Wittstock M,Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, & Ziegler SG (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med, 361, 1651-1661.
27. Glik A, Masarwa M, Abuful A, Deeb A, Strugatsky R, Farrer LA, Friedland RP, & Inzelberg R (2009) Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. Mov Disord, 24, 119-122.
28. Masalha R, Kordysh E, Alpert G, Hallak M, Morad M, Mahajnah M, Farkas P, & Herishanu Y (2010) The prevalence of Parkinson's disease in an Arab population, Wadi Ara, Israel. Isr Med Assoc J, 12, 32-35.
29. Anca M, Paleacu D, Shabtai H, & Giladi N (2002) Crosssectional study of the prevalence of Parkinson's disease in the Kibbutz movement in Israel. Neuroepidemiology, 21, 50-55. (Pubitemid 34042862)
30. Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, & RoccaWA(2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol, 60, 91-96. (Pubitemid 36078114)
31. Alves G, Muller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, Tysnes OB, & Larsen JP (2009) Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry, 80, 851-857.
32. Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, Bowron A,Walker R, Findley L, Foster O, Patel K, Clough C, Castleton B, Smith S, Carey G, Murphy T, Hill J, Brechany U, McGee P, Reading S, Brand G, Kelly L, Breen K, Ford S, Baker M, Williams A, Hearne J, Qizilbash, & N, Chaudhuri KR (2007) A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry, 78, 465-469. (Pubitemid 46662892)